Portage Biotech Reports FY25 Financial Results: Net Loss Decreases by $68.6 Million

Portage Biotech reported a net loss of $6.8 million for FY25, down from $75.4 million in FY24. Operating expenses decreased to $7.4 million, down from $18.2 million in FY24. R&D expenses dropped by 75% to $3.1 million, mainly due to lower clinical trial costs and manufacturing expenses. The company incurred lower non-cash expenses, contributing to the decrease in net loss.